Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943383 · ClinicalTrials.gov registry record
Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 21
- Enrollment target
NCT01943383 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 21 participants.
The verdict
NCT01943383 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
Patients enrolled in this study will have completed one of the parent studies "Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how well their blood pressure was controlled by medication. Patients in the current study will provide a single tube of blood which will be used to create adult stem cells that can be converted into other cell types, like heart or vasculature. Patients will not be asked to return for any follow up visits.
Interventions
- GENETIC iPSC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01943383
The ClinicalTrials.gov registry entry for NCT01943383 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iPSC is the first listed.
NCT01943383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01943383 about?
NCT01943383 is a clinical study titled "Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study". Patients enrolled in this study will have completed one of the parent studies "Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how well their blood pressure was controlled by medication. Patients in the current study will provide a single tube of blood which w...
What is the current status of trial NCT01943383?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2013-08. Estimated completion is 2018-05.
What interventions are being tested in trial NCT01943383?
The interventions under investigation include: iPSC (GENETIC).
Who is sponsoring clinical trial NCT01943383?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.